# Cost-Effectiveness Analysis of Canagliflozin 300 mg Versus Dapagliflozin 10 mg Added to Metformin in Patients with Type 2 Diabetes in the United States

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/cost-effectiveness-analysis-of-canagliflozin-300-mg-versus-dapagliflozin-10-mg/

## Facts

| Field | Value |
| --- | --- |
| Author Names | C. Neslusan,Anna Teschemaker,Michael Willis,Pierre Johansen,Lien Vo |
| Citations | 24 |
| DOI | 10.1007/s13300-018-0371-y |
| Fields | Medicine |
| Open Access | true |
| OA Status | gold |
| OA URL | https://link.springer.com/content/pdf/10.1007/s13300-018-0371-y.pdf |
| OpenAlex ID | https://openalex.org/W2787518873 |
| PMID | 29411292 |
| Type | article |
| Year | 2018 |

## Paper authors

- [C. Neslusan](https://scholariq.org/researchers/c-neslusan/)

## Paper journal

- [Diabetes Therapy](https://scholariq.org/journals/diabetes-therapy/)

## Paper primary topic

- [Diabetes Treatment and Management](https://scholariq.org/topics/diabetes-treatment-and-management/)

## Paper topics

- [Diabetes Treatment and Management](https://scholariq.org/topics/diabetes-treatment-and-management/)
- [Pancreatic function and diabetes](https://scholariq.org/topics/pancreatic-function-and-diabetes/)
- [Diabetes Management and Research](https://scholariq.org/topics/diabetes-management-and-research/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.